Bioxytran (BIXT) Income from Non-Controlling Interests (2021 - 2024)
Bioxytran (BIXT) posted Income from Non-Controlling Interests of -$13324.0 for Q1 2024, up 38.95% sequentially from -$21823.0 in Q4 2023, and up 59.49% YoY from -$8353.9 in Q2 2023.
Bioxytran (BIXT) Income from Non-Controlling Interests (2021 - 2024) Analysis & Trends
Bioxytran has reported Income from Non-Controlling Interests for 4 years, with the latest figure at -$13324.0 in Q1 2024.
- Quarterly Income from Non-Controlling Interests rose 59.49% year-over-year to -$13324.0 in Q1 2024, while the trailing twelve-month figure through Dec 2024 was -$13324.0 (up 85.24% YoY) and the FY2024 annual result came in at -$13324.0, up 85.24% from the prior year.
- Income from Non-Controlling Interests advanced to -$13324.0 in Q1 2024 per BIXT's latest filing, from -$21823.0 in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $39782.0 in Q4 2021 and troughed at -$246935.0 in Q2 2021.
- A 4-year average of -$61019.3 and a median of -$34777.0 in 2023 frame the typical range for Income from Non-Controlling Interests.
- The widest YoY moves for Income from Non-Controlling Interests: up 95.27% in 2022, down 228.34% in 2022.
- Over 4 years, Income from Non-Controlling Interests stood at $39782.0 in 2021, then plunged by 228.34% to -$51058.0 in 2022, then jumped by 57.26% to -$21823.0 in 2023, then jumped by 38.95% to -$13324.0 in 2024.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered -$13324.0, -$21823.0, and -$34777.0 for Q1 2024, Q4 2023, and Q3 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -13,324.00 |
| Dec 31, 2023 | -21,823.00 |
| Sep 30, 2023 | -34,777.00 |
| Jun 30, 2023 | -764.00 |
| Mar 31, 2023 | -32,894.00 |
| Dec 31, 2022 | -51,058.00 |
| Sep 30, 2022 | -79,507.00 |
| Jun 30, 2022 | -11,691.00 |
| Mar 31, 2022 | -51,116.00 |
| Dec 31, 2021 | 39,782.00 |
| Sep 30, 2021 | -134,530.00 |
| Jun 30, 2021 | -246,935.00 |
| Mar 31, 2021 | -154,614.00 |